ECSP992897A - INTEGRIN RECEPTOR ANTAGONISTS - Google Patents

INTEGRIN RECEPTOR ANTAGONISTS

Info

Publication number
ECSP992897A
ECSP992897A ECSP992897A ECSP992897A EC SP992897 A ECSP992897 A EC SP992897A EC SP992897 A ECSP992897 A EC SP992897A EC SP992897 A ECSP992897 A EC SP992897A
Authority
EC
Ecuador
Prior art keywords
receptor antagonists
integrin receptor
alpha
compounds
present
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Paul J Coleman
Robert S Meissner
Jiabing Wang
Mark E Duggan
Wasyl Halczenko
John H Hutchinson
Ben C Askew
Michael A Patane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP992897 priority Critical patent/ECSP992897A/en
Publication of ECSP992897A publication Critical patent/ECSP992897A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos y derivados de los mismos, su sintesis, y su uso como antagonistas del receptor integrina. Más particularmente los compuestos de la presente invención son antagonistas de los receptores integrina alfa vB3, alfa v b5, y/o, av b6 y son útiles para inhibir la resorción ósea, tratar y prevenir osteoporosis, e inhibir la resyenosis vascular, retinopatia diabética, degeneración macular, angiogenésis, ateroesclerosis, inflamación, cicatrización de heridas, enfermedad viral y crecimiento de tumos y metástasis.The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly the compounds of the present invention are alpha vB3, alpha v b5, and / or av b6 receptor antagonists and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular resyenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.

ECSP992897 1999-03-24 1999-03-24 INTEGRIN RECEPTOR ANTAGONISTS ECSP992897A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP992897 ECSP992897A (en) 1999-03-24 1999-03-24 INTEGRIN RECEPTOR ANTAGONISTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP992897 ECSP992897A (en) 1999-03-24 1999-03-24 INTEGRIN RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ECSP992897A true ECSP992897A (en) 1999-06-01

Family

ID=42043885

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP992897 ECSP992897A (en) 1999-03-24 1999-03-24 INTEGRIN RECEPTOR ANTAGONISTS

Country Status (1)

Country Link
EC (1) ECSP992897A (en)

Similar Documents

Publication Publication Date Title
ATE298338T1 (en) INTEGRIN RECEPTOR ANTAGONISTS
ATE294163T1 (en) INTEGRIN RECEPTOR ANTAGONISTS
ATE299023T1 (en) INTEGRIN RECEPTOR ANTAGONISTS
DK1187592T3 (en) Alpha v integrin receptor antagonists
ATE236626T1 (en) INTEGRIN ANTAGONIST
ES2185009T3 (en) ALFA AND BETA 3 'ANTAGONISTS.
ATE353219T1 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
ECSP992897A (en) INTEGRIN RECEPTOR ANTAGONISTS
YU38300A (en) Integrin receptor antagonists
YU38200A (en) Integrin receptor antagonists
ECSP003775A (en) INTEGRIN ALFA V RECEIVER ANTAGONISTS